Education
About Us
Working with TipRanks
Follow Us
Mayne Pharma Group (AU:MYX)
ASX:MYX
Total Valuation
Mayne Pharma Group has a market cap or net worth of AU$567.10M. The enterprise value is AU$269.89M.
Market CapAU$567.10M
Enterprise ValueAU$269.89M
Share Statistics
Mayne Pharma Group has 81.25M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding81.25M
Owned by Insiders0.07%
Owned by Instutions<0.01%
Financial Efficiency
Mayne Pharma Group’s return on equity (ROE) is -0.38 and return on invested capital (ROIC) is -4.88%.
Return on Equity (ROE)-38.36%
Return on Assets (ROA)-15.24%
Return on Invested Capital (ROIC)-4.88%
Return on Capital Employed (ROCE)-5.53%
Revenue Per Employee―
Profits Per Employee―
Employee Count
Asset Turnover0.34
Inventory Turnover2.27
Valuation Ratios
The current PE Ratio of Mayne Pharma Group is -2.12. Mayne Pharma Group’s PEG ratio is 0.05.
PE Ratio-2.12
PS Ratio0.95
PB Ratio0.81
Price to Fair Value0.81
Price to FCF-10.22
Price to Operating Cash Flow-24.15
PEG Ratio0.05
Income Statement
In the last 12 months, Mayne Pharma Group had revenue of AU$413.53M and earned -AU$129.23M in profits. Earnings per share was -AU$1.48.
RevenueAU$413.53M
Gross ProfitAU$243.85M
Operating Income-AU$13.60M
Pretax Income-AU$129.94M
Net Income-AU$129.23M
EBITDA47.87M
Earnings Per Share (EPS)-1.48
Cash Flow
In the last 12 months, operating cash flow was AU$391.00K and capital expenditures -AU$11.65M, giving a free cash flow of -AU$11.26M billion.
Operating Cash FlowAU$391.00K
Free Cash Flow-AU$11.26M
Free Cash Flow per Share-AU$0.14
Dividends & Yields
Mayne Pharma Group pays an annual dividend of AU$0.03, resulting in a dividend yield of
Dividend Per ShareAU$0.03
Dividend Yield
Payout Ratio
Free Cash Flow Yield-9.79%
Earnings Yield-47.16%
Stock Price Statistics
Beta0.28
52-Week Price Change0.29%
50-Day Moving Average6.69
200-Day Moving Average5.11
Relative Strength Index (RSI)48.43
Average Volume (3m)740.52K
Important Dates
Mayne Pharma Group upcoming earnings date is Aug 21, 2025, TBA.
Last Earnings DateFeb 25, 2025
Next Earnings DateAug 21, 2025
Ex-Dividend DateJan 18, 2023
Financial Position
Mayne Pharma Group as a current ratio of 1.47, with Debt / Equity ratio of 0.09
Current Ratio1.47
Quick Ratio1.23
Debt to Market Cap0.09
Net Debt to EBITDA0.61
Interest Coverage Ratio-1.33
Taxes
In the past 12 months, Mayne Pharma Group has paid -AU$11.90M in taxes.
Income Tax-AU$11.90M
Effective Tax Rate11.29%
Enterprise Valuation
Mayne Pharma Group EV to EBITDA ratio is -2.55, with an EV/FCF ratio of -8.25.
EV to Sales0.77
EV to EBITDA-2.55
EV to Free Cash Flow-8.25
EV to Operating Cash Flow-19.49
Balance Sheet
Mayne Pharma Group has AU$124.91M in cash and marketable securities with AU$39.87M in debt, giving a net cash position of -AU$85.05M billion.
Cash & Marketable SecuritiesAU$124.91M
Total DebtAU$39.87M
Net Cash-AU$85.05M
Net Cash Per Share-AU$1.05
Tangible Book Value Per Share-AU$1.44
Margins
Gross margin is 56.30%, with operating margin of -11.81%, and net profit margin of -44.89%.
Gross Margin56.30%
Operating Margin-11.81%
Pretax Margin-48.97%
Net Profit Margin-44.89%
EBITDA Margin-30.12%
EBIT Margin-40.08%
Analyst Forecast
The average price target for Mayne Pharma Group is AU$7.52, which is 11.43% higher than the current price. The consensus rating is Hold
Price TargetAU$7.52
Price Target Upside7.70%
Analyst ConsensusHold
Analyst Count2
Revenue Growth Forecast52.96%
EPS Growth Forecast45.68%